{ "Phase 2 Study of CRD-4730 for CPVT", "This study is testing an investigational medicine called CRD-4730 for people with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT is a heart condition that can cause dangerous heart rhythms. The study aims to understand how safe CRD-4730 is, how well your body handles it, and its effects. You may be able to join if you are 18 or older and have a confirmed CPVT diagnosis, including a specific genetic mutation (RYR2). The study will compare different doses of CRD-4730 with a placebo (an inactive pill that looks like the study medicine). The main goal is to look at changes from the start of the study up to Day 101.", "design": "This is a Phase 2, randomized, double-blind, placebo-controlled study with 12 participants. It involves comparing two doses of CRD-4730 with a placebo.", "commitments": "You will receive two different doses of CRD-4730 and one dose of a matching placebo over three periods. The primary outcomes are measured from Baseline to Day 101.", "compensation": "Not stated in the trial record.", "follow_up": "The primary outcomes are measured up to Day 101 after the start of the study.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.